Bepridil hydrochloride hydrate is a potent calcium channel blocker/antagonist and class IV anti-arrhythmic agent once used to treat angina but is no longer on the market.

O4I1 (O4-I1; O4I-1; O4I 1) is a novel and potent inducer of Oct3/4 (POU5F1 and Oct4) with potential usefulness as a regenerative medicine.

BAYK 8644 [(+/-)-Bay K-8644] is a novel and potent L-type Ca2+ channel activator with an EC50 of 17.3 nM.

Mibefradil (formerly Ro-405967; Ro 40-5967; trade name: Posicor), an approved drug that can be used for the treatment of hypertension and chronic angina pectoris, is a calcium channel blocker/CCB with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.

Tezacaftor (formerly VX-661; VX661; VX 661; trade name: Symdeko) is a second F508del CFTR corrector with antifibrotic effects and is also one of three components in the fixed-dose combination medication (cocktail: Elexacaftor/tezacaftor/ivacaftor, Trikafta and Kaftrio) used in patients who have cystic fibrosis with a F508del mutation.

Aranidipine is a novel and potent calcium channel blocker.

Amlodipine (formerly UK-48340; Norvasc; used as as besylate, mesylate or maleate salts) is a selective and long-acting CCB-calcium channel blocker that belongs to the dihydropyridine (DHP) class.

Gallopamil HCl (Methoxyverapamil HCl), a methoxy analog of Verapamil, is a a coronary vasodilator and a phenylalkylamine calcium antagonist.

SR33805 is a novel and potent antagonist of Ca2+ channel with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively, and it blocks L-type but not T-type Ca2+ channels.

Suvecaltamide (MK8998; compound 33; MK-8998) is a novel potent and selective antagonist of the T-type calcium channel that is being investigated as a potential new therapeutic for the treatment of schizophrenia.